FDA Issues Warning About Unapproved Ophthalmic Balanced Salt Solution Drug Products

It appears that the FDA is requiring certain manufacturers of balanced salt solutions (BSS) to cease and desist from manufacturing these products on or before November 24, 2008. You can read the FDA release here. If you use these products, the only “approved” manufacturers, as of this article (published Oct. 1, 2008), are Alcon and Akorn.

Advertisement

You should develop an action plan to secure these products — at this time — from your Alcon or Akorn BSS sources. From the bulletin, the issue relates to licensure and not specific lot numbers of the products from “unapproved companies.”

Acceptable manufacturers and NDA numbers are:

  • Alcon NDA BSS #20-742
  • Alcon NDA BSS Plus #18-469
  • Akorn NDA #75-503
  • Akorn Endosol Extra NDA# 20-079

Note: This article comes from a recent edition of Pharm-ASC, a weekly e-mail publication by Sheldon S. Sones, RPh, FASCP, a Newington, Conn.-based consultant, pharmacist and safe medication officer serving more than 100 ASCs in the Northeast. Learn more at www.sheldonsones.com.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in ASC Accreditation, Licensure & Medicare Certification

Advertisement

Comments are closed.